Novartis' (NVS.US) new 1st-class radioactive cancer therapy has been approved for clinical trials in China.
Monday, Mar 3, 2025 8:40 am ET
1min read On March 3, the National Medical Products Administration's (NMPA) Center for Drug Evaluation (CDE) officially announced that novartis (NVS.US) had been approved to conduct clinical trials for its 1st-class new drug [225Ac]Ac-PSMA-617 injection, which is intended to treat metastatic hormone-resistant prostate cancer positive for PSMA after [177Lu]Lu-PSMA targeted therapy. According to Novartis' pipeline information on its website, this is a radioactive ligand therapy targeting PSMA (development code: AAA817), which has entered the 2/3 phase clinical research stage in the international market. This is the first time the product has been approved for IND in China.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.